A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
NCT01616303 is a phase 2 interventional trial sponsored by Quest PharmaTech Inc.. As of 21 Nov 2026, it is completed. It studies Carboplatin, Paclitaxel and Oregovomab in Ovarian Neoplasms. The registry lists an enrollment of 97 participants at 2 sites in 1 country. The registry lists a start date of 15 Jun 2012 and a primary completion date of 15 Jun 2015.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT01616303 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Quest PharmaTech Inc. |
| Enrollment | 97 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Ovarian Neoplasms |
| Drugs | Carboplatin, Paclitaxel and Oregovomab |
| Start | 15 Jun 2012 |
| Primary completion | 15 Jun 2015 |
| Study completion | 12 Oct 2018 |
| Last update posted | 14 Sept 2020 |
| Other registry IDs | EU-CTR / CTIS (EudraCT) 2010-024305-13 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Christopher Nicodemus, MD FACP
AIT Strategies
Study Chair - Thomas Woo, M.Sc.
Quest PharmaTech Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Connecticut Health Center
Farmington
- Northern Indiana Cancer Research Consortium
South Bend
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT01616303
Each answer restates registry values shown on this page.
What is NCT01616303?
NCT01616303 is a phase 2 interventional trial sponsored by Quest PharmaTech Inc.. It studies Carboplatin, Paclitaxel and Oregovomab in Ovarian Neoplasms.
Who leads NCT01616303?
The registry names Christopher Nicodemus, MD FACP (study chair, AIT Strategies) and Thomas Woo, M.Sc. (study director, Quest PharmaTech Inc.) as overall officials.
Where does NCT01616303 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT01616303 study?
The registered drug and biological interventions are Carboplatin, Paclitaxel and Oregovomab.
When did NCT01616303 end?
The registry lists a primary completion date of 15 Jun 2015 and a study completion date of 12 Oct 2018. The sponsor last updated the record on 14 Sept 2020.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.